Definitive Contract HHSN272201300018C
Award Date
9/12/13
Potential Completion Date
1/20/15
Potential Value
$846K
Federal Agency
NIAID DEA OA Acquisitions
Awardee
Trius Therapeutics, Inc.
Ultimate Awardee
Cubist Pharmaceuticals, Inc.
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
28
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a new contract award by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to Trius Therapeutics, Inc., a for-profit organization. The contract, awarded under Broad Agency Announcement NIH-NIAID-DMID-08-20, is a definitive, cost-plus-fixed-fee contract with a ceiling value of $25,641,873.40 and an ultimate completion date of August 31, 2013. The contract does not have a set-aside designation. As NIAID is...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Emory University. The $3,458,502.19 cost-no-fee contract is for "TARGETING THERAPEUTICS DEVELOPMENT TO RELIEVE BOTTLENECKS: OPTIMIZONG LEAD THERAPEUTIC COMPOUNDS AGAINST INFECTIOUS PATHOGENS." It has a period of performance through October 31, 2018. The contract is not designated as a set-aside. The contract has several...
This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the "DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES", which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...
This is a $6,335,456.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Technical Resources International, Inc. (TRI), a minority-owned, woman-owned, and Hispanic American-owned small business. The contract is for regulatory operations support services and has a period of performance through March 30, 2030. TRI has extensive experience supporting...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Biocryst Pharmaceuticals Inc., a biotechnology company specializing in small molecule drugs for rare diseases. The $47,755,722.77 cost-plus-fixed-fee contract is for the development of medical countermeasures for biodefense and emerging infectious diseases. The contract has a base period from September 16, 2013, to September 15, 2017, with two option periods...
This is a definitive cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to Technical Resources International, Inc. (TRI), a minority-owned, woman-owned, and Hispanic American-owned small business. The $31,946,661.00 contract provides regulatory affairs support services for the Division of Microbiology and Infectious Diseases (DMID) at NIAID. This includes scientific,...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The $99,299 cost-plus-fixed-fee delivery order was placed under the Therapeutics Against Infectious Diseases Phase 1 IDIQ contract, which funds Phase I clinical trials for therapeutic products targeting infectious diseases. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General Dynamics...
This is a $24,457,189.99 cost-plus-award-fee definitive contract awarded to Technical Resources International, Inc. (TRI), a minority-owned, woman-owned, Hispanic American-owned small business, by the National Institute of Allergy and Infectious Diseases (NIAID). The contract is for the Regulatory Compliance Center, a set-aside for total small businesses, with a period of performance ending on August 12, 2016. TRI is an experienced provider of comprehensive clinical research support services...
This is a $3,044,549.00 fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for biomedical research and development work, with a period of performance ending on March 31, 2010. No set-aside designations were used. Resilience Government Services, a technology-focused biomanufacturing company, has...
The federal contract award HHSN272201100404P was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to Trionix Research Laboratory, Inc. on March 24, 2011. The $12,000 firm fixed-price purchase order contract has a completion date of September 30, 2011. The contract does not have a set-aside designation. Based on the award description of "TRIONIX (AMBIS #1547194)", this contract is likely for research and development services related to the AMBIS program, which...